Valley Brook Capital Group Inc. Boosts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Valley Brook Capital Group Inc. lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,885 shares of the medical research company’s stock after buying an additional 25 shares during the quarter. Thermo Fisher Scientific makes up 2.2% of Valley Brook Capital Group Inc.’s investment portfolio, making the stock its 11th largest position. Valley Brook Capital Group Inc.’s holdings in Thermo Fisher Scientific were worth $3,022,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of TMO. Kornitzer Capital Management Inc. KS boosted its holdings in shares of Thermo Fisher Scientific by 2.0% during the third quarter. Kornitzer Capital Management Inc. KS now owns 7,209 shares of the medical research company’s stock worth $4,459,000 after purchasing an additional 140 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Thermo Fisher Scientific by 22.1% in the 3rd quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company’s stock worth $771,876,000 after buying an additional 225,568 shares during the last quarter. Montecito Bank & Trust grew its holdings in Thermo Fisher Scientific by 3.8% in the 3rd quarter. Montecito Bank & Trust now owns 3,612 shares of the medical research company’s stock valued at $2,234,000 after buying an additional 131 shares during the period. Jackson Square Capital LLC increased its stake in shares of Thermo Fisher Scientific by 70.6% during the 3rd quarter. Jackson Square Capital LLC now owns 10,310 shares of the medical research company’s stock valued at $6,377,000 after acquiring an additional 4,268 shares during the last quarter. Finally, Graypoint LLC boosted its position in shares of Thermo Fisher Scientific by 1.4% in the third quarter. Graypoint LLC now owns 2,992 shares of the medical research company’s stock worth $1,851,000 after acquiring an additional 41 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

TMO has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price target on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Redburn Atlantic assumed coverage on Thermo Fisher Scientific in a report on Monday, October 14th. They issued a “buy” rating and a $680.00 target price on the stock. Royal Bank of Canada dropped their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Finally, TD Cowen raised their price target on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $649.33.

Thermo Fisher Scientific Stock Up 0.1 %

NYSE TMO traded up $0.30 during trading hours on Thursday, reaching $559.98. 102,639 shares of the company traded hands, compared to its average volume of 1,454,589. The stock has a market capitalization of $214.19 billion, a PE ratio of 35.09, a PEG ratio of 3.67 and a beta of 0.79. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12 month low of $437.26 and a 12 month high of $627.88. The company has a 50 day moving average of $596.33 and a two-hundred day moving average of $583.80.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same period last year, the firm earned $5.69 earnings per share. The company’s revenue for the quarter was up .2% compared to the same quarter last year. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the sale, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at approximately $67,175,513.68. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the transaction, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at approximately $67,175,513.68. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the sale, the executive vice president now directly owns 16,663 shares in the company, valued at approximately $9,333,946.08. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,150 shares of company stock worth $10,094,925 over the last ninety days. 0.34% of the stock is owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.